GlassScriptPhysician profile
Wesley B Garner
NPI 1285154484
$3,001.17
in general payments reported to CMS, 2019-2025
40 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $619 · 2024: $906 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $379.42 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $360.01 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Novartis Pharmaceuticals Corporation | $256.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $254.36 | 2023-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $214.81 | 2023-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $167.90 | 2023-2025 | Libtayo |
| Brainlab, INC. | $115.78 | 2022-2025 | Brainlab, INC. |
| Iovance Biotherapeutics, INC. | $113.91 | 2024-2025 | Amtagvi |
| Sobi, INC | $97.68 | 2022-2025 | |
| Eisai INC. | $81.99 | 2022-2025 | |
| Amgen INC. | $77.09 | 2022-2023 | Lumakras |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.80 | 2022-2023 | Gilotrif |
| Jazz Pharmaceuticals INC. | $61.90 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.74 | 2024-2025 | Fruzaqla |
| Genmab U.S., INC. | $43.99 | 2023-2025 | Epkinly |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $43.61 | 2024-2025 | Onivyde |
| Tersera Therapeutics LLC | $43.50 | 2023 | Zoladex, Xermelo |
| Array Biopharma INC | $41.31 | 2023-2024 | Xalkori, Lorbrena, Mektovi |
| Incyte Corporation | $41.11 | 2023-2025 | Monjuvi, Jakafi |
| Pharmacosmos Therapeutics INC. | $37.39 | 2024-2025 | Monoferric, Cosela |
| Sumitomo Pharma America, INC. | $35.44 | 2023-2024 | Orgovyx |
| Genentech USA, INC. | $34.89 | 2024 | Alecensa, Tecentriq |
| Genzyme Corporation | $34.48 | 2025 | |
| Adc Therapeutics America, INC. | $33.09 | 2024-2025 | |
| Lilly USA, LLC | $29.89 | 2023-2024 | Retevmo, Verzenio |
| Novocure INC. | $29.88 | 2023 | Optune |
| Aveo Pharmaceuticals, INC. | $27.09 | 2023-2025 | Fotivda |
| Seagen INC. | $26.33 | 2023 | Adcetris, Tukysa |
| Exelixis INC. | $26.15 | 2023-2025 | Cabometyx |
| Emd Serono, INC. | $20.70 | 2025 | |
| Mirati Therapeutics, INC. | $19.20 | 2024 | Krazati |
| Pharmaessentia USA Corporation | $17.64 | 2023 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $17.40 | 2024 | |
| Dendreon Pharmaceuticals LLC | $17.27 | 2025 | Provenge |
| Geron Corporation | $16.97 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $16.65 | 2024 | Sylvant |
| Kyowa Kirin, INC. | $15.37 | 2025 | |
| Puma Biotechnology, INC. | $13.68 | 2023 | |
| Beigene USA, INC. | $13.07 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $13.07 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.